Treatment modalities for fever duration in children with Mycoplasma pneumoniae pneumonia
Treatment modalities for fever duration in children with Mycoplasma pneumoniae pneumonia
About this item
Full title
Author / Creator
Kang, Dayun , Yun, Ki Wook , Lee, Taekjin , Cho, Eun Young , Eun, Byung Wook , Lee, Joon Kee , Kim, Yae-Jean , Kim, Doo Ri , Shin, Areum , Kang, Hyun Mi , Kim, Ye Ji , Kim, Dong Hyun , Choi, Young June , Lee, Hyunju , Cho, Youngmin , Kwak, Byung Ok , Jo, Kyo Jin , Choi, Jae Hong , Choi, Eun Hwa and Park, Su Eun
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Mycoplasma pneumoniae
is the leading cause of community-acquired pneumonia in children. With increasing macrolide resistance, the use of second-line antibiotics such as tetracyclines and quinolones is also increasing. Clinical data were collected from 13 institutions between September 2023 and February 2024. MPP was defined as the detection of
Alternative Titles
Full title
Treatment modalities for fever duration in children with Mycoplasma pneumoniae pneumonia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_35090790307b481db5f027864977d9b7
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_35090790307b481db5f027864977d9b7
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-025-99537-0
